Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Brief Crisis Therapy for Suicidal Children and Adolescents (IPT-A-SCI)

8 juin 2026 mis à jour par: Chamutal Saragusty, Tel Aviv University

Ultra-Brief Crisis IPT-A Based Intervention for Suicidal Children and Adolescents (IPT-A-SCI): Understanding Mechanisms of Change

The goal of this clinical trial is to learn if the Ultra-Brief Interpersonal Psychotherapy for Adolescents with Suicidal Ideation (IPT-A-SCI) works to reduce suicidal thoughts and behaviors in children and adolescents. The study will also examine whether treatment effects continue after treatment ends and whether some participants benefit more from the intervention than others. The main questions it aims to answer are:

Does IPT-A-SCI reduce suicidal thoughts and behaviors in children and adolescents? Do the effects of IPT-A-SCI continue three months after treatment ends? Do some children and adolescents benefit more from IPT-A-SCI than others?

Participants will:

Receive IPT-A-SCI treatment consisting of five weekly sessions Complete questionnaires before treatment, during treatment, at the end of treatment, and three months after treatment ends Have their parents complete questionnaires at the same time points

Aperçu de l'étude

Statut

Pas encore de recrutement

Intervention / Traitement

Description détaillée

IPT-A-SCI (Ultra-Brief Crisis Interpersonal Psychotherapy for Adolescents with Suicidal Ideation) is a manualized five-session crisis intervention based on Interpersonal Psychotherapy (IPT) principles.

IPT-A-SCI is designed for children and adolescents aged 8-18 presenting with suicidal ideation or behavior. The intervention combines IPT principles with the Safety Planning Intervention and includes a three-month post-intervention contact protocol.

This is a single-group, pre-post interventional study with repeated measures collected at four time points. All participants will receive the IPT-A-SCI intervention. There is no control or comparison group in this study, as the research focuses on within-person mechanisms of change and moderators of treatment response rather than between-group comparisons.

Participants will be recruited from the Child and Adolescent Clinic at Geha Mental Health Center through emergency room referrals, outpatient providers, and treating therapists at the clinic. Initial evaluation and suicide risk assessment will be conducted by experienced clinical staff according to established clinical guidelines for suicide risk assessment in adolescents.

Up to 120 participants will be enrolled over an estimated two-year recruitment period.

During the three months following treatment, participants will receive three personalized emails at 2 weeks, 1 month, and 2 months post-treatment. A follow-up session will take place three months after treatment completion. Psychiatric or psychosocial treatment may continue as usual during IPT-A-SCI.

Statistical Analysis Plan:

Three complementary analytic frameworks will be used:

  1. Modeling within-person change across therapy
  2. Examining associations between changes in proposed mechanisms of change and changes in suicidality
  3. Identifying participant characteristics associated with differential treatment response Individual Growth Curve Modeling (IGCM) will be used to examine trajectories of change across the four assessment time points for proposed mechanisms of change, including hope, perceived social support, emotional processing, family conflict, and interpersonal functioning.

Latent Change Score (LCS) modeling will be used to assess changes in suicidal ideation and related clinical outcomes from baseline to post-treatment and follow-up. Associations between changes in proposed mechanisms and changes in suicidality will be examined to identify factors that may contribute to treatment effectiveness.

Linear Mixed-Effects Models (LMMs) will be used to examine whether treatment effectiveness varies according to baseline participant characteristics, including initial suicide risk severity and other demographic and clinical variables. These analyses will identify moderators of treatment response and determine which participants derive the greatest benefit from the intervention.

Missing data will be handled in accordance with established best practices for longitudinal clinical research. The analytic approaches described above accommodate missing data under missing-at-random assumptions.

Data Collection and Management:

  • Questionnaires will be completed by participants and parents at all assessment time points.
  • The Columbia-Suicide Severity Rating Scale (C-SSRS) will be administered by clinicians during treatment sessions.
  • A unique trial identification number will be assigned at recruitment and used across all study materials.
  • All study data will be retained in accordance with Good Clinical Practice (GCP) guidelines.

Safety Monitoring and Ethical Considerations:

This study focuses on children and adolescents at risk for suicide. The Child and Adolescent Clinic at Geha Mental Health Center is located on the grounds of a psychiatric hospital with a 24/7 emergency room. Participants presenting with acute suicidal crisis during the study may be referred immediately for emergency psychiatric evaluation.

All treating clinicians are trained in suicide risk assessment and management. Adverse events, including worsening suicidal ideation or behavior, will be documented and reported in accordance with Helsinki Committee requirements and Good Clinical Practice guidelines.

No formal Data Safety Monitoring Board (DSMB) is in place for this study given its single-site naturalistic design. Clinical oversight will be provided through routine supervision and case conferencing.

Type d'étude

Interventionnel

Inscription (Estimé)

120

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Petah Tikva, Israël
        • Geha Mental Health Center
        • Contact:
        • Chercheur principal:
          • Chamutal Saragusty, MA

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Enfant
  • Adulte

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • Children and adolescents aged 8-18 years presenting with suicidal ideation or behavior
  • Suicide risk assessment indicating suitability for outpatient treatment,
  • Fluency in Hebrew
  • Ability to attend five weekly treatment sessions
  • Written informed consent provided by parents or legal guardians
  • Written informed assent/consent provided by participants in accordance with age and local ethical regulations

Exclusion Criteria:

  • Acute medical or psychiatric condition requiring immediate inpatient treatment
  • Linguistic, developmental, neurological, or intellectual limitations that prevent understanding of the treatment protocol or study procedures
  • Inability to participate in outpatient psychotherapy

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: IPT-A-SCI
Participants will receive the IPT-A-SCI intervention consisting of five weekly sessions of ultra-brief interpersonal psychotherapy combined with safety planning for suicidal ideation and behavior.
Manualized ultra-brief interpersonal psychotherapy intervention combined with safety planning for children and adolescents with suicidal ideation or behavior.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in Severity of Suicidal Ideation
Délai: Baseline to 3-month follow-up
Change in severity of suicidal ideation and behavior assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS). The C-SSRS assesses the severity of suicidal ideation and the occurrence of suicidal behaviors. The suicidal ideation severity score ranges from 1 to 5, with higher scores indicating greater severity of suicidal ideation.
Baseline to 3-month follow-up

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in Intensity of Suicidal Ideation
Délai: Baseline to 3-month follow-up
Change in intensity of suicidal ideation assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS) ideation intensity scale. The C-SSRS assesses the intensity of the most severe suicidal ideation endorsed by evaluating five dimensions: frequency, duration, controllability, deterrents, and reasons for ideation. Total scores range from 0 to 25, with a score of 0 assigned when no suicidal ideation is endorsed and scores from 2 to 25 indicating increasing intensity of suicidal ideation. Higher scores indicate more intense suicidal ideation and a worse outcome.
Baseline to 3-month follow-up
Change in Depressive Symptoms
Délai: Baseline to 3-month follow-up
Change in depressive symptoms assessed using the Short Mood and Feelings Questionnaire (SMFQ). Scores range from 0 to 26, with higher scores indicating greater depressive symptom severity and a worse outcome.
Baseline to 3-month follow-up
Change in Perceived Social Support
Délai: Baseline to 3-month follow-up
Change in perceived social support assessed using the Multidimensional Scale of Perceived Social Support (MSPSS). Scores range from 12 to 84, with higher scores indicating greater perceived social support and a better outcome.
Baseline to 3-month follow-up
Change in Emotional Processing (Alexithymia)
Délai: Baseline to 3-month follow-up
Change in emotional processing and alexithymia assessed using the Toronto Alexithymia Scale (TAS-20). Scores range from 20 to 100, with higher scores indicating greater difficulty identifying and describing emotions (greater alexithymia) and a worse outcome.
Baseline to 3-month follow-up
Change in Hope
Délai: Baseline to 3-month follow-up
Change in hope assessed using the Children's Hope Scale (CHS). Scores range from 6 to 36, with higher scores indicating greater hopefulness and a better outcome.
Baseline to 3-month follow-up
Change in Family Conflict and Interpersonal Stress
Délai: Baseline to 3-month follow-up
Change in family conflict and interpersonal stress assessed using the Family Environment Scale (FES) conflict subscale. Scores range from 0 to 9, with higher scores indicating greater family conflict and a worse outcome.
Baseline to 3-month follow-up
Change in Irritability and Emotional Dysregulation
Délai: Baseline to 3-month follow-up
Change in irritability and emotional dysregulation assessed using the parent-report TIDES-13 questionnaire. Total scores range from 13 to 91, with higher scores indicating greater irritability and emotional dysregulation and a worse outcome.
Baseline to 3-month follow-up
Change in Interpersonal and Social Functioning
Délai: Baseline to 3-month follow-up
Change in interpersonal and social functioning assessed using EFORTS social routine measures. Scores range from 0 to 5. with higher scores indicating better social routine functioning and executive functioning in daily activities and therefore a better outcome.
Baseline to 3-month follow-up
Behavioral and Emotional Problems at Baseline
Délai: Baseline only
Behavioral and emotional problems assessed using the parent-report Child Behavior Checklist (CBCL). This measure will be used for descriptive and covariate analyses. Raw scores vary according to age and sex and are converted to standardized T-scores. Higher T-scores indicate greater emotional and behavioral problems and a worse outcome.
Baseline only

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Collaborateurs

Les enquêteurs

  • Chercheur principal: Chamutal Saragusty, MA, Geha Mental Health Center and Tel Aviv University

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 juin 2026

Achèvement primaire (Estimé)

1 juin 2028

Achèvement de l'étude (Estimé)

1 juin 2028

Dates d'inscription aux études

Première soumission

30 mai 2026

Première soumission répondant aux critères de contrôle qualité

30 mai 2026

Première publication (Réel)

4 juin 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

11 juin 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

8 juin 2026

Dernière vérification

1 juin 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner